- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr David M. O'Malley on Identifying Which Patients Will Respond to PARP Inhibitors
We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.
We're getting better at identifying which patients with ovarian cancer will respond to poly ADP-ribose polymerase (PARP) inhibitors, but we have a long way to go, said David M. O'Malley, MD, professor of medicine, Department of Gynecology, and director of Gynecologic Oncology Clinical Research at the James Cancer Center, Ohio State University.
Transcript
Are we getting better at identifying which patients with ovarian cancer will respond better to PARP inhibitors?
I think we’re getting better, but we still have a long way to go. Between the BRCA testing, other HRD [homologous recombination deficiency] genes and mutations, as well as, for example, methylation of the BRCA, RAD51C and RAD51D, we’re identifying more and more patients that clearly should have PARP as a maintenance program. We will continue to identify those patients, for example, of loss of heterozygosity or the HRD positive patients that will help us separate those who we should be treating with PARP versus antivascular therapy.
In addition, with some of the ongoing phase 3 trials, we may find that combination therapy, particularly in those that are wildtype, will be our best path forward.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
